Affinity Asset Advisors, LLC
CIK 1773195 · Holdings on Sep 30, 2024 · First reported Nov 13, 2024
Top ten holdings
Q3 2024- XENE6.99%
- APGE6.05%
- NUVL5.36%
- ACLX5.18%
- ALKS4.34%
- TEVAN3.91%
- MDGL3.29%
- CRNX3.17%
- NRIX3.00%
- VERA2.98%
Share classes counted separately44.27%
Portfolio value by quarter
What changed this quarter?
Within preview · weight change- NUVLWeight increased · +2.97 pp2.39% → 5.36%Shares +137.50K (+68.75%)
- ALKSWeight increased · +1.87 pp2.47% → 4.34%Shares +350.00K (+53.85%)
- MDGLWeight decreased · -1.56 pp4.85% → 3.29%Shares -10.00K (-9.09%)
Weight = security value ÷ total reported holdings value. Changes are in percentage points; price moves also affect weights, so they are not trade sizes.
Top 10 holdings 25
USD · B = billion · M = million; expand a row for exact values| # | Security | Value | Weight | Quantity | Weight / quantity change | Activity | |
|---|---|---|---|---|---|---|---|
| 01 | XENEXENON PHARMACEUTICALS INC View history and evidence | $45.04M | 6.99% | 1.14M shares | 6.11% → 6.99%+0.88 pp +149.79K (+15.07%) | Added | ↗▾ |
| 02 | APGEAPOGEE THERAPEUTICS INC View history and evidence | $39.01M | 6.05% | 664.20K shares | 5.18% → 6.05%+0.87 pp -172.09K (-20.58%) | Reduced | ↗▾ |
| 03 | NUVLNUVALENT INC-A View history and evidence | $34.53M | 5.36% | 337.50K shares | 2.39% → 5.36%+2.97 pp +137.50K (+68.75%) | Added | ↗▾ |
| 04 | ACLXARCELLX INCCOMMON STOCK View history and evidence | $33.40M | 5.18% | 400.00K shares | 4.00% → 5.18%+1.18 pp -60.00K (-13.04%) | Reduced | ↗▾ |
| 05 | ALKSALKERMES PLCSHS View history and evidence | $27.99M | 4.34% | 1.00M shares | 2.47% → 4.34%+1.87 pp +350.00K (+53.85%) | Added | ↗▾ |
| 06 | TEVANTEVA PHARMACEUTICAL-SP ADRSPONSORED ADS View history and evidence | $25.23M | 3.91% | 1.40M shares | 3.71% → 3.91%+0.20 pp -50.00K (-3.45%) | Reduced | ↗▾ |
| 07 | MDGLMADRIGAL PHARMACEUTICALS INC View history and evidence | $21.22M | 3.29% | 100.00K shares | 4.85% → 3.29%-1.56 pp -10.00K (-9.09%) | Reduced | ↗▾ |
| 08 | CRNXCRINETICS PHARMACEUTICALS IN View history and evidence | $20.44M | 3.17% | 400.00K shares | 3.63% → 3.17%-0.46 pp -115.00K (-22.33%) | Reduced | ↗▾ |
| 09 | NRIXNURIX THERAPEUTICS INC View history and evidence | $19.33M | 3.00% | 860.40K shares | 3.00% → 3.00%+0.00 pp -51.60K (-5.66%) | Reduced | ↗▾ |
| 10 | VERAVERA THERAPEUTICS INCCL A View history and evidence | $19.23M | 2.98% | 435.00K shares | 2.14% → 2.98%+0.84 pp +60.00K (+16.00%) | Added | ↗▾ |
Options overlay 9
$88.24M notionalPut and Call positions are separate. Notional is based on underlying securities, not option premium, market value or net exposure. Quantities are underlying shares.
| Security | Put / Call | Underlying shares | Notional | Quantity change | |
|---|---|---|---|---|---|
FLNAFILANA THERAPEUTICS INC View history and evidence | Put | 1.45M | $42.65M | +1.45M | ▾ |
TEVANTEVA PHARMACEUTICAL-SP ADRSPONSORED ADS View history and evidence | Call | 1.00M | $18.02M | -150.00K (-13.04%) | ▾ |
ANABANAPTYSBIO INC View history and evidence | Put | 200.00K | $6.70M | +200.00K | ▾ |
3 / 9 options · preview only
Exited positions 30
| Security | Type | Shares out | Value out | Previous filing | This filing |
|---|---|---|---|---|---|
| SPY SS SPDR S&P 500 ETF TRUST-US | Put | -350,000 | -$190.48M | SEC filing ↗ | SEC filing ↗ |
| 15678U128 CEREVEL THERAPEUTICS HOLDING | Non-derivative | -500,000 | -$20.45M | SEC filing ↗ | SEC filing ↗ |
| 10806XAB8 BRIDGEBIO PHARMA INC | Non-derivative | -17,000,000 | -$17.26M | SEC filing ↗ | SEC filing ↗ |
3 / 30 preview exits. Up to 30 exit records are previewed. Exit means absent from the current filing; execution date, price and proceeds are unknown.
Every number has a source.
CIK 1773195 · Period 2024-09-30
Data loaded 2026-09-23 · First reported 2024-11-13
Amendments and versions
{
"amendments_merged": null,
"prior_versions": null,
"cover_table_value": 732761256
}Research all 86 reported holdings.
This page includes 30 of 86 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.
- Download CSV
- Earlier quarters
- Advanced screening & filtering
- API & AI access
＋ New accounts get free API credits to explore data beyond ownership filings.
For AI agents & developers
The initial HTML of this page carries its exact data as script#portfolio-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account. This page lists 30 of 86 current positions (options included); totals and weights use the complete filing.
Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.
MCP https://api.akkrudata.ai/mcp
get_institutional_portfolio
{"cik":"1773195","quarter":"2024Q3","page_size":100}
get_institutional_manager_history
{"cik":"1773195","page_size":100}Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.
- MCP endpoint
- https://api.akkrudata.ai/mcp
- API / MCP documentation
- /documents
- llms.txt
- /llms.txt
Sources, coverage & how to read this data
Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.